Welcome to the Precigen, Inc. virtual shareholder meeting. I would now like to introduce our first speaker, Randal J. Kirk, Chairman.
Good morning. I'm RJ Kirk, chairman of the board of directors of Precigen, and I would like to welcome each of you to our annual meeting of shareholders. To all of our shareholders, I wish you the best for you, your families, and your communities. I'm also pleased to welcome the other members of our board, including Dr. Helen Sabzevari, Precigen's President and CEO. I hereby call this meeting of shareholders to order and ask Don Lehr, our Chief Legal Officer, who will serve as secretary of the meeting, to continue with the proceedings. Don?
Thank you, RJ. We're hosting today's meeting through a virtual meeting platform, and rules and procedures have been posted on the platform. If anyone experiences technical issues related to participation in the meeting, please call the phone number listed on the portal site. Attending this meeting today is Ms. Kathy Weeden, who's been appointed as Inspector of Election to tabulate and certify the votes pursuant to the company's bylaws. Also attending this meeting is Beth Ann Reese, a representative of Deloitte & Touche, which acts as the company's independent registered public accounting firm for 2025 and which Precigen has proposed as its independent public accounting firm for 2026. Ms. Reese will be available during the meeting to address applicable questions. The company received an affidavit made by Joanne Vogel of Broadridge Financial Solutions stating that on April 30th, 2026, due notice of this meeting was properly mailed.
The affidavit will be filed with the minutes of the meeting. The company's 2025 annual report and 2026 proxy statement have been made available to shareholders online as well as by mail if so requested. I now ask Ms. Weeden what is the total number of shares and votes present or represented at this meeting?
Shareholders holding at least 273,738,349 shares of the company's common stock are present by proxy. These shares constitute more than 76% of the total number of votes entitled to be cast at the meeting based on the shares outstanding at the close of business on April 17th, 2026, the record date for this meeting.
Thank you. There's a quorum and the meeting can proceed. Shareholders are being asked to vote on each of the four proposals listed in the proxy statement. There are no other proposals to be considered at the meeting today. Any shareholder or shareholder representative who desires to comment on a proposal may do so by submitting a comment using the designated field on the web portal. After the votes have been counted, we'll receive the report of the Assistant Inspector of Election, which will conclude the official business of the meeting, and shareholders may submit their comments and questions using the designated field on the annual meeting web portal at any time during this meeting. RJ, with your approval, we would now consider each proposal discussed in the proxy statement.
Please proceed.
The first order of business is the proposal to elect the following nine individuals to the company's board of directors: Randal J. Kirk, Cesar Alvarez, Steve Frank, Vinita Gupta, Fred Hassan, Jeffrey Kindler, Nancy Howell Agee, Helen Sabzevari, and James Turley, each to serve a one-year term expiring at the earlier of the next annual meeting or until his or her successor is duly qualified and elected and qualified. Are there any questions or comments regarding this proposal?
No questions or comments have been received.
The second order of business is to ratify the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026, as described in the proxy. Are there any questions or comments regarding this proposal?
No questions or comments have been received.
The third order of business is the proposal to approve a non-binding advisory resolution approving the compensation of the named executive officers as described in the proxy. Are there any questions or comments regarding this proposal?
No questions or comments have been received.
The fourth and final order of business is a proposal to approve an amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan as described in the proxy. Are there any questions or comments regarding this proposal?
No questions or comments have been received.
Okay. We will now therefore proceed with a vote to approve each of the four proposals before the shareholders. I can hereby declare the voting closed. Ms. Weeden, would you please make a preliminary report on the results of the voting?
Having tabulated the votes cast, I find that at least 153,102,933, or 72% of the number of votes properly cast, were cast for each of the election of each of the nine nominees for director. At least 272,812,598, or 99% of the number of votes properly cast, were cast in favor of the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026. At least 208,241,070, or 98% of the number of votes properly cast, were cast in favor of the approval of the non-binding advisory resolution approving the compensation of the named executive officers. At least 207,055,596, or 97% of the number of votes properly cast, were cast in favor of the approval of the amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan.
Thank you. Based on these results, I'm pleased to declare that all the director nominees have been elected and that each of the additional three proposals presented to the shareholders have been approved or ratified. The Inspector of Elections final report on the results of the voting will be filed with the minutes of the meeting, and we will report the final vote results in a Form 8-K. This concludes the formal business of the annual meeting. We will now address any additional shareholder questions.
There are no questions that have been received.
Seeing that no questions have been received at this time, this will conclude the question and answer period. On behalf of Mr. Kirk, Dr. Sabzevari, our board, and the entire management team, I thank each of you for attending and for your continued interest in and support of Precigen. The meeting is adjourned.
The meeting has now concluded. Thank you for attending today's presentation. You may now disconnect.